Pasar al contenido principal

PROMOCION DE LA TOMA DE DECISIONES COMPARTIDAS EN CRIBADO OPORTUNISTA EN CANCER DE PROSTATA

PI20/01334

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD MIGUEL HERNANDEZ
Centro realización UNIVERSIDAD MIGUEL HERNANDEZ

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Knowledge and practices regarding prostate cancer screening in Spanish men, The importance of personal and clinical characteristics (PROSHADE study)

  • Parker, Lucy A.
  • Caballero-Romeu, Juan-Pablo|||0000-0002-5737-6047
  • Chilet-Rosell, Elisa
  • Hernandez-Aguado, Ildefonso
  • Gómez-Pérez, Luis|||0000-0003-1396-0484
  • Alonso-Coello, Pablo|||0000-0002-8001-8504
  • Cebrián-Cuenca, Ana M.|||0000-0003-3710-6370
  • López-Garrigós, Maite
  • Moral Peláez, Irene|||0000-0002-3842-8796
  • Ronda, Elena
  • Gilabert, Mercedes
  • Canelo Aybar, Carlos Gilberto|||0000-0002-0844-4365
  • Párraga-Martínez, Ignacio
  • del Campo-Giménez, Maria
  • Lumbreras Lacarra, Blanca|||0000-0003-1665-0860
Patients' decisions on prostate cancer (PCa) opportunistic screening may vary. This study aimed to assess how demographic and health-related characteristics may influence knowledge and decisions regarding PCa screening. A cross-sectional survey was conducted among men aged over 40, randomly sampled from the Spanish population, 2022. The survey underwent development and content validation using a modified Delphi method and was administered via telephone. Binomial logistic regression was used to explore the relationship between respondents' characteristics and participants' knowledge and practices concerning PCa and the PSA test. Out of 1,334 men, 1,067 (80%) respondents were interviewed with a mean age of 58.6 years (sd 11.9). Most had secondary or university studies (787, 73.8%) and 61 (5.7%) selfreported their health status as bad or very bad. Most of the respondents (1,018, 95.4%) had knowledge regarding PCa with nearly 70% expressed significant concern about its potential development (720, 70.8%), particularly among those under 64 years (p = 0.001). Out of 847 respondents, 573 (67.7%) reported that they have knowledge regarding the PSA test: 374 (65.4%) reported receiving information from a clinicians, 324 (86.6%) information about the benefits of the test and 189 (49,5%) about its risks, with differences based on educational background. In a multivariable analysis (adjusted for age, educational level and previous prostate problems), respondents with higher levels of education were more likely to have higher knowledge regarding the PSA test (OR 1.75, 95%CI 1.24-2.50, p<0.001). Although most of the patients reported to have knowledge regarding PCa, half of the interviewed men reported knowledge about PSA test. Differences in knowledge prostate cancer screening and undesirable consequences highlight the need to develop and provide tailored information for patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of patients' age and comorbidities on prostate cancer overdiagnosis in clinical practice

  • Beltrán, A.
  • Parker, L.
  • Moral-Pérez, I.
  • Caballero-Romeu, J.P.
  • Chilet-Rosell, E.
  • Hernández-Aguado, I.
  • Alonso-Coello, Pablo|||0000-0002-8001-8504
  • Ronda Pérez, Elena|||0000-0003-1886-466X
  • Gómez-Pérez, L.
  • Lumbreras Lacarra, Blanca|||0000-0003-1665-0860
Introduction Overdiagnosis in PSA-based prostate cancer (PCa) screening is primarily studied in younger, healthier populations from clinical trials. This study aimed to evaluate the probability of overdiagnosis in PCa screening within a clinical practice context, focusing on its relationship with PSA levels, Gleason scores, and subsequent clinical procedures. Methods We conducted a retrospective cohort analysis of 1,070 asymptomatic men over 40 years old diagnosed with PCa between 2004 and 2022, following a positive PSA test. The patients were followed until December 31, 2022, with a median follow-up time of 5.7 years (IQR 3.2-8.6). The primary outcome was the probability of overdiagnosis, assessed through life expectancy and the Charlson Comorbidity Index, considering lead times of 5, 10, and 15 years. Results We found that patients with PSA levels.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Perspectives of clinicians and screening candidates on shared decision-making in prostate cancer screening with the prostate-specific antigen (PSA) test, A qualitative study (PROSHADE study)

  • Guilabert, Mercedes|||0000-0002-0706-9911
  • Parker, Lucy A.
  • Chilet-Rosell, Elisa
  • Gómez-Pérez, Luis|||0000-0003-1396-0484
  • Alonso-Coello, Pablo|||0000-0002-8001-8504
  • Cebrián-Cuenca, Ana M.|||0000-0003-3710-6370
  • López-Garrigós, Maite
  • Moral Peláez, Irene|||0000-0002-3842-8796
  • Ronda Pérez, Elena|||0000-0003-1886-466X
  • Canelo Aybar, Carlos Gilberto|||0000-0002-0844-4365
  • Hernández-Aguado, Ildefonso
  • Lumbreras Lacarra, Blanca|||0000-0003-1665-0860
  • Sanchis, María José
  • Caballero-Romeu, Juan-Pablo|||0000-0002-5737-6047
  • Párraga Martínez, Ignacio
  • del Campo-Giménez, Maria
Objective The objective of this study is to analyse the perspectives of screening candidates and healthcare professionals on shared decision-making (SDM) in prostate cancer (PCa) screening using the prostate-specific antigen (PSA) test. Design Descriptive qualitative study (May-December 2022): six face-to-face focus groups and four semistructured interviews were conducted, transcribed verbatim and thematically analysed using ATLAS.ti software. Setting Data were obtained as part of the project PROSHADE (Decision Aid for Promoting Shared Decision Making in Opportunistic Screening for Prostate Cancer) to develop a tool for SDM in PCa screening with PSA testing in Spain. Participants A total of 27 screening candidates (three groups of men: 40-50 years old; 51-60 years old and 61-80 years old), 25 primary care professionals (one group of eight nurses and two groups of physicians: one with more and one with less than 10 years of experience), and four urologists. Focus groups for patients and healthcare professionals were conducted separately. Main outcome measures Participants' perceptions of shared decision-making related to PSA opportunistic screening, including their understanding, preferences, and attitudes. Results Three themes were generated: (1) perceptions of SDM, (2) perceptions of PSA testing and (3) perceptions of SDM regarding PCa screening. Theme 1: screening candidates valued SDM when it included clear information and empowered them. There was consensus with primary care health professionals on this point, although their knowledge and implementation of SDM varied. Theme 2: candidates were divided on PSA testing; some trusted it for early detection, while others expressed scepticism due to concerns about false positives and invasive procedures, reflecting gaps in accessible information. Theme 3: Professionals across primary and specialised care stressed the need for standardised SDM protocols. Primary care physicians were particularly concerned that PSA decisions align with scientific evidence and urologists recognised SDM as valuable in PSA testing only if it was adequately explained to each patient. Barriers to implementing SDM included insufficient coordination across care levels, lack of consensus-driven protocols and limited clinical time. Conclusions While patients expect comprehensive information, primarily based on practice to achieve empowerment, healthcare professionals face obstacles such as limited time and insufficient coordination between primary care and urology. All stakeholders agree on the importance of evidence-based tools to reinforce effective SDM and enhance collaboration across urologists and primary care in the context of PSA testing.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

PROSHADE Protocol, Designing and Evaluating a Decision Aid for Promoting Shared Decision Making in Opportunistic Screening for Prostate Cancer: A Mix-Method Study

  • Lumbreras Lacarra, Blanca|||0000-0003-1665-0860
  • Parker, Lucy Anne
  • Alonso-Coello, Pablo|||0000-0002-8001-8504
  • Mira-Bernabeu, Javier
  • Gómez-Pérez, Luis|||0000-0003-1396-0484
  • Caballero-Romeu, Juan-Pablo|||0000-0002-5737-6047
  • Pertusa-Martínez, Salvador|||0000-0002-2990-5570
  • Cebrián-Cuenca, Ana M.|||0000-0003-3710-6370
  • Moral Peláez, Irene|||0000-0002-3842-8796
  • López-Garrigós, Maite
  • Canelo Aybar, Carlos Gilberto|||0000-0002-0844-4365
  • Ronda Pérez, Elena|||0000-0003-1886-466X
  • Guilabert, Mercedes|||0000-0002-0706-9911
  • Prieto-González, Antonio
  • Hernández-Aguado, Ildefonso
Background: Opportunistic prostate-specific antigen (PSA) screening may reduce prostate cancer mortality risk but is associated with false positive results, biopsy complications and overdiagnosis. Although different organisations have emphasised the importance of shared decision making (SDM) to assist men in deciding whether to undergo prostate cancer screening, recent evaluations show that the available decision aids fail to facilitate SDM, mainly because they do not consider the patients' perspective in their design. We aim to systematically develop and test a patient decision aid to promote SDM in prostate cancer screening, following the Knowledge to Action framework. Methods: (1) Feasibility study: a quantitative survey evaluating the population and clinician (urologists and general practitioners) knowledge of the benefits and risks derived from PSA determination and the awareness of the available recommendations. Focus groups to explore the challenges patients and clinicians face when discussing prostate cancer screening, the relevance of a decision aid and how best to integrate it into practice. (2) Patient decision aid development: Based on this data, an evidence-based multicomponent SDM patient decision aid will be developed. (3) User-testing: an assessment of the prototype of the initial patient decision aid through a user-testing design based on mix-methods (questionnaire and semi-structured review). The decision aid will be refined through several iterative cycles of feedback and redesign. (4) Validation: an evaluation of the patient decision aid through a cluster-randomised controlled trial. Discussion: The designed patient decision aid will provide balanced information on screening benefits and risks and should help patients to consider their personal preferences and to take a more active role in decision making. Conclusions: The well-designed patient decision aid (PDA) will provide balanced information on screening benefits and risks and help patients consider their personal preferences.